Group 1: Job Positions - The recruitment includes faculty positions and postdoctoral positions in various research fields such as cancer, tropical pathogens and immunobiology, cardiovascular and metabolic diseases, neuroscience, stem cells and regenerative medicine, and basic medicine [4] - Applicants for faculty positions must hold a PhD or MD/PhD, have completed several years of postdoctoral training or possess relevant industrial research experience, and demonstrate strong independent research capabilities [6][7] - Senior researchers will receive independent lab space, graduate student supervision opportunities, and dedicated funding for research assistants and technical staff [7] Group 2: Compensation and Benefits - Senior researchers will earn an annual salary ranging from 1 million to 1.5 million RMB (pre-tax), while junior researchers will earn between 500,000 and 800,000 RMB (pre-tax) [9] - Research start-up funds are provided, with senior researchers receiving between 6 million and 8 million RMB, and junior researchers receiving 1 million RMB [9] - All faculty members will have access to advanced research facilities, including high-throughput sequencing platforms, confocal microscopy systems, and flow cytometry facilities [9] Group 3: Postdoctoral Researcher Requirements - Candidates for postdoctoral positions should have a solid foundation in their research field, strong scientific literacy, excellent communication skills, and demonstrated innovative potential [11] - Postdoctoral researchers must commit full-time to the position and are not allowed to hold concurrent jobs during their tenure [12] - Preference will be given to candidates with interdisciplinary research experience and a background in tropical medicine or related fields [14] Group 4: Application Materials - Applicants must submit a CV, a 3 to 5-page research plan, and two letters of recommendation [13] - Additional required documents include a copy of the PhD certificate (or official proof of impending graduation) and representative publications [19]

Financial Performance - In 2024, the company achieved a revenue of 64,502.19 million yuan, representing a year-on-year growth of 18.65% [1] - The net profit attributable to shareholders was 12,383.25 million yuan [1] - In Q1 2025, the company reported a revenue of 18,649.04 million yuan, with a year-on-year increase of 27.73% [1] - The net profit for Q1 2025 was 4,057.85 million yuan, reflecting a growth of 32.30% [1] Business Strategy - The company focuses on biomedicine and cell immunotherapy, emphasizing a market-oriented and customer-centric approach [1] - A comprehensive optimization of internal management has been implemented to enhance competitiveness and profitability [1] CGT (Cell and Gene Therapy) Development - The company offers a full range of solutions from drug target discovery to commercial production for cell and gene therapy clients [2] - It has developed a series of recombinant proteins and unique antibodies for CAR-T product development, including a specific antibody targeting CD19 [2] - The company has successfully developed nearly 50 GMP-grade products for CGT applications, ensuring high-quality standards [3] ADC (Antibody-Drug Conjugates) Development - ADCs combine targeted antibodies with potent chemotherapy drugs, minimizing harm to normal cells while maximizing therapeutic effects [4] - The company provides a range of products and services for ADC development, including target proteins and linker enzymes [5] Neuroscience Research - The company focuses on providing high-quality recombinant proteins and neurotrophic factors for brain science research [7] - It has developed products targeting neurodegenerative diseases such as Alzheimer's and Parkinson's, as well as diagnostic proteins [7]